Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Nvidia Develops New Location-Verification Technology for AI Chips 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Jiangsu Hengrui Pharmaceuticals Co (HK:1276) made a powerful entrance on the Hong Kong Stock Exchange on Friday, with shares soaring over 37% in early trading after a $1.27 billion IPO. The offering was priced at HK$44.05—at the top of its range—reflecting strong investor appetite for the Chinese biopharmaceutical giant.
Shares opened at HK$57.10, marking a 29.6% jump from the offer price, and peaked at HK$60.20 shortly after the market opened. The robust debut highlights renewed investor confidence in Hong Kong’s IPO market, which has seen a notable resurgence, particularly from mainland Chinese companies pursuing dual listings.
Hengrui, already publicly traded in Shanghai, is one of China’s top drugmakers, specializing in oncology, innovative therapies, and biosimilars. The company plans to allocate IPO proceeds to accelerate clinical trials, scale production capabilities, and support global expansion. The strategic move is aimed at strengthening its international footprint and enhancing its competitiveness in the global pharmaceutical industry.
The timing of Hengrui’s successful listing coincides with the broader uptick in Hong Kong’s capital markets. Earlier this week, Contemporary Amperex Technology Co Ltd (CATL) (HK:3750) also debuted strongly, underscoring heightened interest in high-growth Chinese firms across sectors.
Jiangsu Hengrui’s performance signals positive momentum for biotech and pharmaceutical IPOs in Asia, particularly as global investors look toward companies with robust pipelines and innovation-driven strategies. With a clear focus on global growth and R&D, Hengrui's dual listing positions it to attract more institutional interest while reinforcing Hong Kong’s status as a hub for health tech and biotech capital.
